低分子量肝素有高危出血患者血液透析中的应用

A low molecular weight heparin use for hemodialysis in patients with a high risk of hemorrage

本文对39例高危出血的急、慢性肾功能衰竭血液透析患者分组应用低分子量肝素(速避凝)和无肝素透析,观察两种透析方法的疗效和对出血危险的影响。结果表明与无肝素透析比较,应用速避凝,体外循环凝血现象少,透析器复用次数多,尿素氮,肌酐清除率高(P<0.01,P<0.001),透析后中空纤维容积下降百分比小(P<0.001);同时观察到两组病例透析后静脉穿刺点压迫止血时间无明显差异(P>0.05),出血危险性均未加重。研究证实速避凝用于高危出血的急、慢性肾功能衰竭血液透析,疗效好,安全性大,无不良反应。

39 cases with high risk of hemorrage of acute and chronic renal failure, were divided into two groups during hemodialysis, one used a low molecular weight heparin (Fraxiparine)as an anticoagulation, the other did without standard heparin(SH), then hemodialysis effects and hemorrage were observed between the two groups.The results showed that using Fraxiparine was better than hemodialysis without SH in coagulation of exienal circulation, frequency of reusing di-azer, clean ureanitrogon and creatininc rate (p<0.01, p<0.001) and, decreasing of hollow fiber volume after hemodialysis(p< 0. 001), andihemoslatic time by pressing vein puncture point was not different between the groups(P >0. 05), hemorrage was not worse after hemodialysis in all cases. It suggesls that Fraxiparine is efficient and safe duriny hemodialysis in patients with acute and chronic renal faiure,and there is no side-effect.